Recursion Pharmaceuticals (RXRX) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Recursion Pharmaceuticals (RXRX) right now is An industrial-scale AI platform and proprietary data moat: Recursion's core argument is that drug discovery becomes a data and compute problem at scale. Revenue (Q1 2026) is ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates). If that keeps playing out, the setup is favourable; the risk to it is the central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. No one can predict where RXRX trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Recursion Pharmaceuticals (RXRX) higher?
An industrial-scale AI platform and proprietary data moat
Recursion's core argument is that drug discovery becomes a data and compute problem at scale. It has run vast numbers of automated biological experiments to build one of the largest proprietary maps of cellular biology, the kind of dataset that is expensive and slow for others to reproduce. The bet is that this data advantage, fed into machine-learning models, can surface drug targets and candidates faster and at lower cost than conventional trial-and-error chemistry.
A deep big-pharma partnership book
Recursion has signed collaborations with major drug makers including Roche-Genentech, Bayer, Sanofi, and Merck KGaA. Management has pointed to more than $20 billion in potential future milestone payments across these deals, before any royalties on net sales. These partnerships validate the platform externally, fund operations with non-dilutive cash, and give Recursion multiple shots on goal without bearing all the clinical cost itself.
The NVIDIA tie and owned supercomputing
Recursion owns BioHive, an NVIDIA-built supercomputer that the company has described as among the most powerful AI systems wholly owned by any biopharma. NVIDIA has been a technology collaborator and investor, reinforcing the narrative that Recursion sits at the intersection of AI infrastructure and biology. Owning its compute lets Recursion train large biological models on its own data without renting capacity from cloud providers.
A broadened, post-merger pipeline
The Exscientia merger combined Recursion's biology-first platform with Exscientia's molecular design and added clinical assets and partnerships. The company now advances several wholly owned Phase 2 programs, including REC-4881 in familial adenomatous polyposis (granted FDA Fast Track and an EU orphan designation) and REC-994 in cerebral cavernous malformation. Pipeline breadth gives the platform several independent chances to produce a clinical win that would re-rate the whole thesis.
What could weigh on RXRX?
The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. AI-driven drug discovery as a category is still unproven at the finish line, and skeptics note that no AI-originated compound has yet delivered a blockbuster approval, leaving open the possibility that the platform advantage does not translate into clinical success. Recursion's Phase 2 candidates could fail in trials like most clinical-stage biotech assets do, and even partnered programs depend on decisions outside Recursion's control. Although the company guides to a cash runway into early 2028, continued losses mean it may need to raise capital again, and equity raises would dilute existing shareholders; the stock has also been volatile, trading well below prior highs.
How to think about a RXRX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the RXRX guide and whether RXRX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the RXRX outlook
The bottom line: what is driving Recursion Pharmaceuticals (RXRX) is An industrial-scale AI platform and proprietary data moat, with revenue (q1 2026) at ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates). If that keeps playing out the setup is favourable; the risk is the central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. No one can predict the price, so treat any RXRX forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around RXRX with Walnut
Use Recursion Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Recursion Pharmaceuticals (RXRX)?
+
No one can reliably predict where RXRX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Recursion Pharmaceuticals higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive RXRX higher?
+
The main growth drivers are An industrial-scale AI platform and proprietary data moat; A deep big-pharma partnership book; The NVIDIA tie and owned supercomputing. Whether they play out is the real question, not a guaranteed path.
What are the risks to RXRX?
+
The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. AI-driven drug discovery as a category is still unproven at the finish line, and skeptics note that no AI-originated compound has yet delivered a blockbuster approval, leaving open the possibility that the platform advantage does not translate into clinical success. Recursion's Phase 2 candidates could fail in trials like most clinical-stage biotech assets do, and even partnered programs depend on decisions outside Recursion's control. Although the company guides to a cash runway into early 2028, continued losses mean it may need to raise capital again, and equity raises would dilute existing shareholders; the stock has also been volatile, trading well below prior highs.
Will RXRX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Recursion Pharmaceuticals's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is RXRX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the RXRX "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.